Syncona portfolio firm Achilles Therapeutics prices US share offering
Syncona portfolio firm Achilles Therapeutics prices US share offering
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreFri, 26th Mar 2021 07:59
Syncona portfolio firm Achilles Therapeutics prices US share offering
Read moreTRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance
Read moreIN BRIEF: Syncona investee Achilles Therapeutics files for US IPO
Read moreIN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test
Read moreSyncona Net Asset Value Dips In Third Quarter, Invests More In Quell
Read more(Sharecast News) - Healthcare investment company Syncona updated the market on its latest quarter on Thursday, reporting clinical, financial and operational progress across its portfolio in the three months ended 31 December.
Read moreSyncona Investee Autolus Nets USD100 Million From ADS Offer
Read more(Sharecast News) - Healthcare investor Syncona said on Wednesday that its portfolio company Autolus Therapeutics has priced its underwritten public offering in the United States at $7.00 per American depositary share (ADS).
Read moreSyncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback
Read moreSyncona Investee Achilles Reports Positive Trial Review, Mulling IPO
Read more(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.
Read moreSyncona Investee Autolus To Focus On Adult Leukemia Programme in 2021
Read more(Sharecast News) - Life science investor Syncona updated the market on its portfolio company Autolus on Wednesday, announcing that it would prioritise the development of the 'AUTO1' programme for adult acute lymphoblastic leukemia (ALL), based on the positive data generated in its phase 1 and 2 studies to date and a high unmet medical need.
Read moreUK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs
Read more